No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

During COVID-19, many research groups sought to develop drugs that target the external surfaces of Spike proteins shared by coronaviruses, which bind to receptor molecules on the surface of host ...

The US Food and Drug Administration has greenlit a next-generation COVID-19 vaccine from Moderna that’s engineered to be given in a smaller dose than the current one and targets certain portions ...

US residents’ ability to get COVID-19 vaccines this fall is about to change as US Food and Drug Administration leaders shift away from a one-size-fits-all approach, raising concerns among ...

FDA recognizes uncertainty in COVID-19 booster efficacy; Invivyd plans innovative monoclonal antibody development for prevention and treatment.

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment. As with its ...

FDA confirms Pemgarda drug effective against dominant COVID-19 variant KP.3.1.1, despite previous concerns. Updates on efficacy against other strains to come.

Journalists covering COVID-19 faced an extraordinarily challenging task of keeping the public informed in a hyper-politicized climate filled with misinformation and reliance on unsubstantiated ...